# Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

> **NCT04932187** · PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

## Interventions

- **DRUG:** Capecitabine, Camrelizumab

## Key facts

- **NCT ID:** NCT04932187
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932187, "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04932187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*